Roadmap for Evaluation of Janssen Ad26.COV2-S (recombinant) vaccine against COVID-19

Overview

In the context of the current public health emergency, regulatory alignment and collaboration are some of the key components that will help to facilitate equitable access to safe and effective vaccines that meet international quality and manufacturing standards. In addition to its procedures for prequalification (PQ) and emergency use listing (EUL) of vaccines, WHO has also developed principles for regulatory collaboration during the scientific review of any vaccine submitted to WHO for assessment.